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Background. *e aim of this study was to compare the daily costs and cost effectiveness of fixed combination glaucoma drugs in
China. Methods. *is study included the following fixed combination drugs: brinzolamide 1% and timolol 0.5% (Azarga; Alcon,
Inc., Fort Worth, TX, USA), travoprost 0.004% and timolol 0.5% (DuoTrav; Alcon, Inc.), bimatoprost 0.03% and timolol 0.5%
(Ganfort; Allergan, Inc., Dublin, Ireland), and latanoprost 0.005% and timolol 0.5% (Xalacom; Pfizer, Inc., New York, NY, USA).
Five bottles of each drug were measured. *e mean actual volume, mean actual number of drops, volume per drop, daily cost,
yearly cost, and permmHg reduction cost for each drug were calculated. Results.*e volumes per drop ranged from 32.61± 2.90 μl
(DuoTrav) to 24.38± 0.23 μl (Ganfort). *e number of usage days per bottle varied from 36 days (DuoTrav) to 61 days (Ganfort).
Azarga had the lowest daily cost ($0.23) and yearly cost ($84.72), while DuoTrav had the highest daily cost ($0.79) and yearly cost
($287.02). Azarga costed $2.17–$3.30 per mmHg intraocular pressure reduction, which was lower than the other three drugs. For
the prostaglandin and ß-adrenergic blocker FCs, Ganfort had the lowest daily cost ($0.35) and per mmHg reduction cost (from
$3.40 to $4.04).Conclusions.*e daily costs of these drugs were significantly different, with Azarga having the lowest daily cost and
best cost effectiveness. For the prostaglandin and β-adrenergic blocker fixed combinations, Ganfort was the most economical
choice with its lower daily cost and per mmHg reduction cost.*e results of this study could provide drug selection guidance from
an economic perspective, but various factors should be considered when making a decision.
1. Introduction
Glaucoma is a disease characterized by the thinning of the
optic nerve fiber layer, a defect in the corresponding visual
field, and irreversible blindness. A high intraocular pressure
(IOP) plays a major role in the onset and progression of
glaucoma, and it is the main controllable factor for glaucoma
[1, 2]. IOP-lowering eye drops, due to their convenience,
effectiveness, and noninvasiveness, continue to be the initial
therapy of choice for most glaucoma patients. However, the
cost of medications has become not only the main risk
factors for poor compliance in patients with glaucoma [3, 4]
but also an important national issue. Variations in costs
among antiglaucoma medications may affect decisions by
managed care administrators, as well as prescribing
clinicians, and can cause a high impact in public health
budget [5–8]. When considering the fact that glaucoma
patients often use medications for a long time, the cost
estimations of different IOP-lowering eye drops are very
important and meaningful, especially for a country with a
large population density and a great number of glaucoma
patients, such as China. Currently, there are several anti-
glaucoma medications available, including prostaglandins,
β-adrenergic blockers, α-adrenergic agonists, cholinergics,
carbonic anhydrase inhibitors, and the newly introduced
fixed combinations (FCs). FCs can reduce the flushing effect
between different drugs, decrease the total usage frequency
of drugs, and minimize the damage to the ocular surface
caused by glaucoma medications and preservatives [9], and
thus improve compliance. At present, several researchers
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from different countries have compared the daily costs of
various antiglaucomamedications [10–13], but FCs were not
included in most of the published papers. In this study, we
aimed to compare the daily costs and cost effectiveness of the
FCs currently available in China.
In China, from the data of National Medical Products
Administration (http://www.app1.sfda.gov.cn) at January 2,
2020, five FCs are available, including brinzolamide 1% and
timolol 0.5% (Azarga; Alcon, Inc., Fort Worth, TX, USA),
travoprost 0.004% and timolol 0.5% (DuoTrav; Alcon, Inc.),
bimatoprost 0.03% and timolol 0.5% (Ganfort; Allergan,
Inc., Dublin, Ireland), latanoprost 0.005% and timolol 0.5%
(Xalacom; Pfizer, Inc., New York, NY, USA), and brimo-
nidine 0.2% and timolol 0.5% (Combigan; Allergan, Inc.,
Dublin, Ireland). However, Combigan is available in only
one or two hospitals in China and was not enrolled for
analysis in our current study. *e price of Ganfort and
Xalacom is uniform in China, $21.55 and $27.23, respec-
tively. *e price of Azarga and DuoTrav varies in different
provinces, and we collected all the prices of Azarga and
DuoTrav, and the median value was used for analysis
(Azarga, $10.34, ranged from $9.83 to $10.36; DuoTrav,
$28.23, ranged from $27.52 to $32.32).
2. Materials and Methods
*e Azarga, DuoTrav, Ganfort, and Xalacom FCs that were
included in this research were ordered fromwholesalers.*e
DuoTrav and Xalacom were labeled as containing 2.5ml per
bottle. Each bottle of Ganfort was labeled 3ml, and each
bottle of Azarga was labeled 5ml. Five bottles of each
medication (all imported oversea) were chosen randomly,
and they were kept at a suitable temperature before the test.
For each test, the bottles were left to stand for a while at
25°C until the liquid in the bottle did not flow. After the
bottle was rotated 180°, the same researcher slowly squeezed
the bottle to ensure that only one drop dropped out; then,
the bottle was put back for a while to stop the liquid from
flowing. *is process was repeated until the bottle was
empty. *e drops were collected in a 5ml tube with in-
crements of 0.1ml, and each number of drops was calculated
in the same environment. *e researcher ensured that the
tube was clean and dry before the next bottle measurement.
Afterwards, the mean actual volume and the mean actual
number of drops for each drug were obtained. *e mean
volume per bottle divided by the mean number of drops per
bottle gave the mean volume per drop.
Assuming that these drugs were used in both eyes and
that one drop of each drug could be successfully dropped
into the conjunctival sac each time, the number of usage days
per bottle was calculated by dividing the mean number of
drops per bottle by the number of drops per day for both
eyes. *e price of each drop was calculated by dividing the
unit price of each bottle by the mean number of drops per
bottle. *e price per drop multiplied by the number of drops
per day equaled the price per day for each medication. *e
price per year for each drug was calculated by multiplying
the price of the drug per day by 365 days per year.
Cost effectiveness was calculated by dividing the drug
cost by the degree of the IOP reduction (mmHg), which is
considered the efficacy of the drug, over the course of the
study period [14]. *e price per day of each drug multiplied
by the number of days studied equals the drug cost during
the study. *e ranges of IOP reduction of glaucoma fixed
combinations were obtained from published data [15–18]. In
order to ensure the homogeneity of different studies, studies
with similar study period (about 3 months) were selected.
Furthermore, all the selected studies were prospective,
randomized, double-masked, or evaluator-masked parallel
group clinical trials. *e participants were mostly open-
angle glaucoma or ocular hypertension patients, and all the
IOP were measured by Goldmann applanation tonometry.
Analysis of variance (ANOVA) was used to compare
daily cost among the groups. *e post hoc least significant
difference (LSD) test was used for multiple comparisons. A
P< 0.05 was considered statistically significant. *e SPSS
17.0 software (SPSS Inc., Chicago, IL, USA) was used for all
statistical analyses.
3. Results
*e mean actual volume, mean actual number of drops,
mean volume per drop, and number of usage days per bottle
are shown in Table 1. *e actual volume per bottle was a bit
different from the labeled volume. *e mean actual volume
per bottle of DuoTrav and Xalacom was 2.33ml and 2.66ml,
respectively, which was labeled as 2.5ml. *e mean actual
volume per bottle of Ganfort and Azarga was 2.98ml and
4.71ml, respectively, while the labeled volume was 3.0ml
and 5.0ml, respectively. *e mean actual number of drops
ranged from 71.8± 4.15 (DuoTrav) to 178.2± 3.19 (Azarga).
*e largest volume per drop was 32.61± 2.90 μl (DuoTrav),
and the smallest volume per drop was 24.38± 0.23 μl
(Ganfort).
*e number of drops per day, usage time per bottle, price
per bottle, daily cost, and yearly cost of each drug are shown
in Table 2. *e number of usage days per bottle ranged from
36 days (DuoTrav) to 61 days (Ganfort). *e unit price of
these drugs ranged from $10.34 (Azarga) to $28.23 (Xala-
com). Azarga had the lowest daily cost ($0.23) and yearly
cost ($84.72), while DuoTrav had the highest daily cost
($0.79) and yearly cost ($287.02). For prostaglandin and
β-adrenergic blocker FCs, Ganfort had the lowest daily cost
($0.35) and yearly cost ($128.53). *ere is a statistically
significant difference in daily cost among these medications
(ANOVA, P< 0.01; LSD, P< 0.01).
*e detailed study information from the published papers
and the calculated cost effectiveness results are shown in Ta-
ble 3. All the studies lasted about threemonths, and the baseline
IOP was similar. Xalacom had the largest IOP reduction
(ranged from 6.3mmHg to 12.5mmHg), and Azarga yielded a
range of cost effectiveness from $2.17 to $3.30 per mmHg
decrease in IOP, indicating Azarga wasmore cost effective than
DuoTrav, Ganfort, and Xalacom. For the prostaglandin and
β-adrenergic blocker FCs, Ganfort had the lowest per mmHg
reduction cost (from $3.40 to $4.04).
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4. Discussion
In this study, we aimed to compare the daily costs and cost
effectiveness of different FCs in China, and we enrolled all of
the most commonly used FCs available in China. Our results
showed that the daily costs of these drugs were significantly
different. Azarga had the lowest daily cost ($0.23), followed
by Ganfort ($0.35) and Xalacom ($0.56). DuoTrav had the
highest daily cost ($0.79), which was more than three times
that of Azarga. For the prostaglandin and β-adrenergic
blocker FCs, Ganfort had the lowest daily cost, which was
consistent with previous studies [19]. *is might be the
result of the lower price ($21.55), the larger labeled volume
(3.0ml) and actual volume (2.98± 0.02ml) per bottle, and
the less volume (24.38± 0.23 μl) per drop of Ganfort. For the
yearly cost, the variation among the different medications
was much larger. DuoTrav had the highest yearly cost
($287.02), which was twice as much as Ganfort ($128.53),
and the difference in the yearly cost between Azarga and
DuoTrav was $202.30.
In this study, we found that Ganfort had the least drop
volume (24.38± 0.23 μl), followed by Azarga (26.45± 0.41 μl)
and Xalacom (27.22± 0.87 μl), while DuoTrav had the largest
drop volume (32.61± 2.90 μl). *is may have been the result
of different dropper tips and bottle designs and
characteristics, as well as the different physicochemical
properties of each medication, which will determine the
drop size [20]. However, the drop sizes of the same medi-
cation were also different in different studies. Xalacom was
reported to have 81.00± 0.97 drops per bottle, and the drop
volume was 30.87± 0.37 μl [13]. In another study, the drops
per bottle and the drop volumes were reported to be
103± 2.49 and 0.030± 0.000ml for Ganfort and 90± 7.58
and 0.030± 0.003ml for Xalacom, respectively [19], which
were both different from our study. *e drop volumes of
Ganfort (24.38± 0.23 μl) and Xalacom (27.22± 0.87 μl) in
our study were both less than those of previous studies
[13, 19]. *is may be related to the squeezing procedure,
which is another drop size-determining factor. In one study,
5 researchers squeezed the bottles, and the operational errors
from these different researchers might have created varia-
tions in the number of drops of the same medication [11]. In
another study, each bottle was held at approximately 45°,
which might have increased the volume of the drug
remaining in the mouth of the bottle [21]. *erefore, in this
study, all of the bottles were squeezed by one researcher, and
all of the bottles were rotated 180°, squeezed slowly, and put
back to avoid waste, minimize the volume of each drop, and
maximize the number of drops. However, in the real world,
drug waste can be induced by many factors, such as bottle
Table 1: *e mean actual volume, the mean actual number of drops, the mean volume per drop, and the number of usage days per bottle of
glaucoma fixed combinations.
Drug Labeled volume/bottle (ml) Actual mean volume/bottle (ml) No. of drops/bottle (95% CI) Volume/drop (μl) (95% CI)
Azarga 5.0 4.71± 0.06 178.2± 3.19 (174.23–182.17) 26.45± 0.41 (25.93–26.96)
DuoTrav 2.5 2.33± 0.08 71.8± 4.15 (66.65–76.95) 32.61± 2.90 (29.01–36.22)
Ganfort 3.0 2.98± 0.02 122.4± 0.55 (121.72–123.08) 24.38± 0.23 (24.09–24.67)
Xalacom 2.5 2.62± 0.03 96.4± 2.40 (93.05–99.75) 27.22± 0.87 (26.13–28.30)
95% CI: 95% confidential interval.















Azarga BID 4 45 10.34 0.06 0.23 84.72
DuoTrav QD 2 36 28.23 0.40 0.79 287.02
Ganfort QD 2 61 21.55 0.18 0.35 128.53
Xalacom QD 2 48 27.23 0.28 0.56 206.20
∗BID: twice per day; QD: once per day. †1 US dollar� 6.9614 Yuan (based on the exchange rate at January 2, 2020).






















Azarga Sezginet al. 92 57 54.8± 8.5 56.1 24.6–29.9 6.42–9.74 21.16 2.17–3.30
DuoTrav Schumanet al. 90 155 62.4± 10.9 59.4 22.9–25.6 7.0–8.2 71.10 8.67–10.16
Ganfort Goldberget al. 84 283
63.5
(23–86) 57.2 23.8–25.4 7.27–8.55 29.40 3.40–4.04
Xalacom Shin et al. 92 125 64.0± 11.0 53.6 27.9± 3.6 9.4± 3.1 51.52 4.12–8.18
Journal of Ophthalmology 3
direct missing, bottle squeezing, blinking, poor dropper tip
visibility, and shaky hands [22], especially in elderly patients.
*erefore, with the increasing age of glaucoma patients, drug
waste will increase accordingly [23, 24]. In order to reduce
waste and decrease the daily costs of medications, patients
should be instructed to use eye drops correctly, and the
design of the bottle and tip should be improved by man-
ufacturers in order to minimize the drop volume.
In order to evaluate the cost effectiveness of each drug, the
information from published papers was used. Although they
were from different trials, the study period and the IOP
baseline was similar, and the reduction of IOPwas also similar.
Holló et al. had compared a variety of studies and confirmed
that DuoTrav, Ganfort, and Xalacom had the similar effects in
IOP reduction [25]. According to our results, the cost effec-
tiveness of Azarga is the best. Ganfort costs 3.40–4.04 $/mmHg
decrease in IOP and had the best cost effectiveness in the
combination of prostaglandins and β-adrenergic blockers,
which is consistent with a study from Spain [26].
Nowadays, glaucoma FCs are becoming more and more
recognized and accepted by the public. Although FCs can ef-
fectively reduce the IOP, decrease the drug use frequency, and
relieve ocular surface damage, the costs of FCs are higher [19].
*e costs ofmedications have been proven to be amajor concern
in drug selection, and it is recommended to communicate with
patients at the time of prescribing in order to improvemedication
compliance, especially in developing countries [27, 28].
We acknowledge the limitations of our study. First, this
study was based on a best-case scenario, which did not involve
the expiration dates of the drugs, daily wastes of the drugs,
drug supplementation frequency, and ineffectiveness of the
drugs. Second, the price of medications may change, although
the standard market price in China for each medication is
regulated by national agency. However, the results of our
study, especially the average number of drops per bottle or
average number of days for usage per bottle, may be useful to
recalculate an updated daily cost when the price changes.
5. Conclusions
In conclusion, the daily costs of FCswere significantly different,
with Azarga having the lowest daily cost and best cost effec-
tiveness. For the prostaglandin and β-adrenergic blocker fixed
combinations, Ganfort was themost economical choice with its
lower daily cost and per mmHg reduction cost. To the best of
our knowledge, our study is the first to compare the daily costs
and cost effectiveness of all of the FCs available in China, which
should provide guidance for drug selection in the future.
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